Down-regulation of vascular endothelial growth factor receptor 2 is a major molecular determinant of proteasome inhibitor-mediated antiangiogenic action in endothelial cells

Cancer Research

Volumn 69, Issue 5, 2009, Pages 1976-1984

  Meissner, Markus ^a   Reichenbach, Gabi ^a   Stein, Monika ^a   Hrgovic, Igor ^a   Kaufmann, Roland ^a   Gille, Jens ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CALPASTATIN; LACTACYSTIN; MESSENGER RNA; TRANSCRIPTION FACTOR SP1; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; PROTEASOME; PROTEINASE INHIBITOR;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BINDING SITE; CAPILLARY; CELL MIGRATION; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; ENDOTHELIUM CELL; GC RICH SEQUENCE; GEL MOBILITY SHIFT ASSAY; GENE REPRESSION; HALF LIFE TIME; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RNA STABILITY; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; PHYSIOLOGY;

ANGIOGENESIS INHIBITORS; BINDING SITES; CELLS, CULTURED; DOWN-REGULATION; ENDOTHELIAL CELLS; HUMANS; PROMOTER REGIONS, GENETIC; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 62449313467     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3150     Document Type: Article

References (46)

1. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-248
2. Carmeliet P, Jain RK. Angiogenesis in. cancer and other diseases. Nature 2000;407:249-257
3. Ferrara N. Role of vascular endothelial growth factor in. the regulation of angiogenesis. Kidney Int I999;56: 794-814.
4. Shibuya M, Ito N, Claesson-Welsh L. Structure and function of vascular endothelial growth factor receptor-1 and-2. Curr Top Microbiol Immunol 1999:237:59-83.
5. Rahimi N, Dayanir "V, Lashkari K. Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-I) modulates mitogenic activity of VEGFR-2 in endothelial cells. J Biol Chem 2000;275: 16986-16992
6. Millauer B, WMgmann-Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest FIk-I as a major regulator of vasculogenesis and. angiogenesis. Cell 1993;72:835-846
7. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin. CH. Different signal transduction, properties of KDR and FlU, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-26995
8. Detmar M. Molecular regulation of angiogenesis in the skin. J Invest Dermatol 1996;106:207-208
9. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J MoI Med 1999:77: 527-543
10. Petrova TV, Makinen T, Alitalo K. Signaling via vascular endothelial growth factor receptors. Exp Cell Res 1999;253:117-30.
11. Schlaeppi J.M, Wood J.M, Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors Cancer Metastasis Rev, 1999, 18, 473-481
12. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003:426: 895-899
13. Muratani M, Tansey WP. How the ublquitln-proteasome system controls transcription. Nat Rev MoI Cell BIoI 2003;4:192-201.
14. Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 2004;16:76-81.
15. Naujokat C, Hoffmann S. Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest 2002;82:965-980
16. Wang T. The 26S proteasome system in the signaling pathways of TGF-ß superfamily. Front Biosci 2003;8: dl 109-127
17. Rajkumar SV Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition, as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-639
18. Mani A, Gelmann EP. The ublquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005;23: 4776-4789
19. Genlnl D, Carbone GM, Catapano CV. Multiple interactions between peroxisome proliferators-activated receptors and the ublquitin-proteasome system and implications for cancer pathogenesis. PPAR Res 2008; 2008:195065.
20. Oikawa T, Sasaki T, Nakamura M, et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998;246:243-8.
21. Mezquita J, Mezquita B, Pau M, Mezquita C. Down-regulation of FlM gene expression by the proteasome inhibitor MG262. J CeE Hochem 2003;89:1138-1147
22. Drexler HC, Rlsau W, Konerdlng MA. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000;14:65-77.
23. Meissner M, Stein M, Urbich C, et al. PPARa activators inhibit vascular endothelial growth factor receptor-2 expression by repressing SpI-dependent DNA binding and transactivation. Circ Res 2004(94: 324-332
24. Meissner M, Pinter A, Michailidou D1 et al. Microtu-bule-targeted drugs inhibit VEGF receptor-2 expression by both transcriptional and post-transcriptional mech-anisms. J Invest Dermatol 2008;128:2084-2091
25. Harada N, Murata Y, Yamaji R, Miura T, Inui H1 Nakano Y. Resveratrol down-regulates the androgen receptor at the post-translational level in prostate cancer cells. J Nutr ScI Vitamino! (Tokyo) 2007;53: 556-560
26. Bross PF, Kane R, Farrell AT, et al. Approval summary for bortezomib for injection, in the treatment of multiple myeloma. Clin Cancer Res 2004;10:3954-3964
27. Utecht KN, Kolesar J. Bortezomib: a novel chemo-therapeutic agent for hematologic malignancies. Am J Health Syst Pharm 2008:65:1221-1231
28. Messersmith WA, Baker SD, Lasslter L, et al. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 2006;12:1270-1275
29. Adams J, Palombella VJ, Sausville EA, et al. Protea-some Inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-2622
30. Shibata T, Imaizumi T, Matsumiya T, et al. Effect of MG.132, a proteasome inhibitor, on the expression of growth related oncogene protein-a in human umbilical vein endothelial cells. Cytokine 2003;24:67-73.
31. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ublquitin-proteasome pathway is required for processing the N.F-KB.1 precursor protein and the activation of NF-KB. CeU 1994;78:773-785
32. Liu. FT, Agrawal SG1 Gribben JG1 et al. Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood 2008;111:2797-2805
33. Fennell DA, Chacko A, Mutti L. BC.L-2 family regulation by the 2OS proteasome inhibitor bortezomib. Oncogene 2008;27:1189-1197
34. Ludwig H, Khayat D, Giaccone G, Façon T. Protea-some inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005:104:1794-1807
35. Roccaro AM, Vacca A, Ribatti D. Bortezomib In the treatment of cancer. Recent Patents Anticancer Drug Discov 2006:1:397-403.
36. Morris MC, Kaiser P, Rudyak S, Baskervllle C, Watson MH, Reed SI. Cksl-dependent proteasome recruitment and activation of CDC20 transcription in budding yeast Nature 2003;423:1009-1013
37. Lipford JR, Deshaies RJ. Diverse roles for ubiquWn-dependent proteolysis in. transcriptional activation. Nat CeU Biol 2003;5:845-850
38. Wlerstra I. SpI: emerging roles-beyond constitutive activation of TATA-less housekeeping genes. Biochem Biophys Res Commun 2008:372:1-13.
39. Chintharlapalil S, Papineni S, Ramaiah SK, Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein, transcription, factors. Cancer Res 2007:67:2816-2823
40. Su K, Yang X, Roos MD, Paterson AJ, Kudlow JE. Human Sug.l/p45 is involved in the proteasome-dependent degradation of SpI. Biochem J 2000:348 Pt 2:281-289
41. Sanüago-Josefat B, Fernandez-Salguero PM. Protea-some inhibition induces nuclear translocation of the dioxin receptor through an. SpI and protein kinase C-dependent pathway. J MoI Biol 2003;333:249-260
42. Wojcik C. Proteasomes in apoptosis: villains or guardians? Cell Mol Life Sei 1999:56:908-917
43. Wojcik C, WiIk S. Changes in proteasome expression and activity during differentiation of neuronal precursor NTera 2 clone Dl cells. Neurochem Int 1999;34:131-136
44. Nawrocki ST, Bruns CJ, Harbison MT, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. MoI Cancer Ther 2002;1:1243-1253
45. Kandasamy K, Kraft AS. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DRS mRNA through the 3'-untranslated region. MoI Cancer Ther 2008;7:1091-1100
46. Paschoud S, Dogar AM, Kuntz C, Grisoni-Neupert B, Richman L, Kuhn LC. Destabilization of interleukin-6 mRNA requires a putative RNA stem-loop structure, an AU-rich element, and the RNA-hinding protein AUFl. MoI CeU Biol 2006;26:8228-8241